BioMarin Pharmaceuticalvs.Gilead Sciences
BMRN vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 18× larger than BioMarin Pharmaceutical by market cap; year to date, Gilead Sciences leads (+19.8% vs −7.6%).
Side by side
| BMRN | GILD | |
|---|---|---|
| Market cap | $10.6B | $186B |
| Price | $54.80 | $151.17 |
| Today | −0.2% | +2.8% |
| Return YTD | −7.6% | +19.8% |
| Return 1Y | +0.4% | +24.4% |
| Since June 26, 2026 | −7.1% | +18.2% |
| P/E | 144.9 | — |
| P/S | 3.1 | 6.1 |
| P/B | 1.7 | 15.7 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →More BMRN & GILD comparisons
Other head-to-heads in the Biotech & innovation segment.